Categories AlphaGraphs, Earnings, Other Industries
Infographic: Key highlights of Signet Jewelers (SIG) Q1 2021 earnings
Signet Jewelers Limited (NYSE: SIG) reported its financial results for the quarter ended May 2, 2020, on Tuesday before the market opens. The results are preliminary due to the pending long-lived non-cash assets impairment review necessitated by the COVID-19 pandemic.

The first-quarter 2021 same-store sales plunged by 38.9% reflecting the temporary closure of all stores beginning in late March due to the COVID-19 pandemic. The company posted a wider loss due to the inclusion of impairment charges against long-lived assets. The total sales dropped by 40.5% year-over-year.
ECommerce sales rose by 6.7%. Excluding the temporary James Allen distribution center shut-down, eCommerce sales grew 18.2%. Signet’s virtual selling efforts led to accelerating consumer demand, with eCommerce growth of 55% in April, excluding the James Allen center impact, and the momentum continued into May.
Consistent with the year-end messaging, Signet’s Board has elected to temporarily suspend the dividend program on the common shares and has elected to pay the August quarterly dividend on its preference shares in kind. The company is not providing fiscal 2021 financial guidance at this time due to the continuing level of uncertainty in the current environment.
Take a look at our Other Industries articles here
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs